Marco Peters - Longboard Pharmaceuticals VP Science
| LBPH Stock | USD 59.80 0.03 0.05% |
Insider
Marco Peters is VP Science of Longboard Pharmaceuticals
| Address | 4275 Executive Square, La Jolla, CA, United States, 92037 |
| Phone | 858 789 9283 |
| Web | https://www.longboardpharma.com |
Longboard Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.3072) % which means that it has lost $0.3072 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4666) %, meaning that it created substantial loss on money invested by shareholders. Longboard Pharmaceuticals' management efficiency ratios could be used to measure how well Longboard Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.13. The current Return On Capital Employed is estimated to decrease to -1.46. As of now, Longboard Pharmaceuticals' Total Current Assets are increasing as compared to previous years.Similar Executives
| Showing other executives | INSIDER Age | ||
| Stewart Fisher | C4 Therapeutics | 57 | |
| Badreddin Edris | Edgewise Therapeutics | 37 | |
| John CPA | MediciNova | N/A | |
| Nicole White | Assembly Biosciences | N/A | |
| MD MPH | MediciNova | 56 | |
| Owen Wallace | Monte Rosa Therapeutics | 55 | |
| Solomon Langermann | NextCure | 64 | |
| Sheri Smith | Celcuity LLC | N/A | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Isabel Aznarez | Stoke Therapeutics | 52 | |
| Reid Leonard | Werewolf Therapeutics | 65 | |
| FACC MD | Stoke Therapeutics | 61 | |
| Oleg Nodelman | Nuvation Bio | 44 | |
| BS CMAR | Champions Oncology | N/A | |
| Adrian Krainer | Stoke Therapeutics | 65 | |
| Kelly Schick | C4 Therapeutics | 44 | |
| Kim Blickenstaff | Nuvation Bio | 68 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| MBA MD | Ikena Oncology | 59 | |
| MBA MBA | Sensei Biotherapeutics | 52 | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
Management Performance
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.31 |
Longboard Pharmaceuticals Leadership Team
Elected by the shareholders, the Longboard Pharmaceuticals' board of directors comprises two types of representatives: Longboard Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Longboard. The board's role is to monitor Longboard Pharmaceuticals' management team and ensure that shareholders' interests are well served. Longboard Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Longboard Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Dewey McLin, VP Affairs | ||
| Jodi Parsons, VP Affairs | ||
| Chadwick MPH, Executive Operations | ||
| Steven JD, Head Counsel | ||
| Randall MD, Executive Officer | ||
| Nuggehally Srinivas, VP Pharmacometrics | ||
| Megan Knight, Head Relations | ||
| Anne Danks, VP Development | ||
| Marco Peters, VP Science | ||
| Kevin Lind, CEO and President | ||
| Gus Cardenas, VP Assurance |
Longboard Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Longboard Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.47 | ||||
| Return On Asset | -0.31 | ||||
| Current Valuation | 2.05 B | ||||
| Shares Outstanding | 34.44 M | ||||
| Shares Owned By Insiders | 1.19 % | ||||
| Shares Owned By Institutions | 98.81 % | ||||
| Number Of Shares Shorted | 1.92 M | ||||
| Price To Book | 8.48 X | ||||
| EBITDA | (56.75 M) | ||||
| Net Income | (54.42 M) |
Currently Active Assets on Macroaxis
When determining whether Longboard Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Longboard Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Longboard Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Longboard Pharmaceuticals Stock:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Longboard Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. For more detail on how to invest in Longboard Stock please use our How to Invest in Longboard Pharmaceuticals guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Longboard Pharmaceuticals. If investors know Longboard will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Longboard Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.25) | Return On Assets (0.31) | Return On Equity (0.47) |
The market value of Longboard Pharmaceuticals is measured differently than its book value, which is the value of Longboard that is recorded on the company's balance sheet. Investors also form their own opinion of Longboard Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Longboard Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Longboard Pharmaceuticals' market value can be influenced by many factors that don't directly affect Longboard Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Longboard Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Longboard Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Longboard Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.